De Novo device
Biolinq Shine Autonomous Time-in-Range Microsensor
Biolinq Incorporated · Glucose Range Monitoring System (SFU, Class II) · First FDA decision Sep 23, 2025, newest Sep 18, 2026Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
0
Naming "Shine Autonomous Time-in-Range"
MAUDE reports
0
Brand "Shine Autonomous Time-in-Range", since 2015
PubMed studies
0
Mentioning "Shine Autonomous Time-in-Range"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Biolinq Shine Autonomous Time-in-Range Microsensor
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K262599 · Decided Sep 18, 2026 · 53 days after receipt
Device type: Glucose Range Monitoring System (SFU) · Laboratory Medicine & Pathology
- Biolinq Shine Autonomous Time-in-Range MicrosensorNew device typeDe Novo
DEN240080 · Decided Sep 23, 2025 · 270 days after receipt
Device type: Glucose Range Monitoring System (SFU) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Home Health Plans of Care: Monitoring Glucose Control in the Medicare Home Health Population with Type II Diabetes MellitusLocal determinationIn effectL35132Palmetto GBAUpdated Apr 9, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "Shine Autonomous Time-in-Range", any status and sponsor, newest update first.
No registered device study names "Shine Autonomous Time-in-Range".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Shine Autonomous Time-in-Range", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SFU
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Shine Autonomous Time-in-Range"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.